The Community Assessment of Psychic Experience (CAPE) questionnaire as a screening-instrument in the detection of individuals at ultra-high risk for psychosis

Schizophrenia Research

Volumn 141, Issue 2-3, 2012, Pages 210-214

  Mossaheb, Nilufar ^a   Becker, Jana ^a,c   Schaefer, Miriam R ^a,b   Klier, Claudia M ^a   Schloegelhofer, Monika ^a   Papageorgiou, Konstantinos ^a   Amminger, G Paul ^a,b  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b ORYGEN RESEARCH CENTRE   (Australia)

^c ALFRIED KRUPP KRANKENHAUS   (Germany)

Author keywords

At risk mental state; CAARMS; CAPE; Prodromal; Psychosis; Ultra high risk

Indexed keywords

ADOLESCENT; ADULT; ARTICLE; CLINICAL ASSESSMENT TOOL; COMMUNITY ASSESSMENT OF PSYCHIC EXPERIENCE QUIESTIONNAIRE; COMPREHENSIVE ASSESSMENT OF AT RISK MENTAL STATES; DIAGNOSTIC TEST ACCURACY STUDY; FEMALE; HIGH RISK POPULATION; HUMAN; MALE; MENTAL HEALTH CARE; PREDICTIVE VALUE; PRIORITY JOURNAL; PSYCHOSIS; QUESTIONNAIRE; RECEIVER OPERATING CHARACTERISTIC; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; STATISTICAL ANALYSIS;

ADOLESCENT; FEMALE; HUMANS; MALE; PSYCHIATRIC STATUS RATING SCALES; PSYCHOTIC DISORDERS; QUESTIONNAIRES; RISK ASSESSMENT; RISK FACTORS; ROC CURVE; SELF REPORT; YOUNG ADULT;

EID: 84866935701     PISSN: 09209964     EISSN: 15732509     Source Type: Journal    
DOI: 10.1016/j.schres.2012.08.008     Document Type: Article

References (27)

1. Amminger G.P., Schaefer M.R., Papageorgiou K., Klier C.M., Cotton S.M., Harrigan S.M., Mackinnon A., McGorry P.D., Berger G.E. Long-chain omega-3 fatty acids for indicated prevention of psychotic disorders: a randomized, placebo-controlled trial. Arch. Gen. Psychiatry 2010, 67(2):146-154.
2. Brenner K., Schmitz N., Pawliuk N., Fathalli F., Joober R., Ciampi A., King S. Validation of the English and French versions of the Community Assessment of Psychic Experiences (CAPE) with a Montreal community sample. Schizophr. Res. 2007, 95(1-3):86-95.
3. Häfner H., Maurer K., Ruhrmann S., Bechdolf A., Klosterkötter J., Wagner M., Maier W., Bottlender R., Möller H.J., Gaebel W., Wölwer W. Early detection and secondary prevention of psychosis: facts and visions. Eur. Arch. Psychiatry Clin. Neurosci. 2004, 254(2):117-128.
4. Heinimaa M., Salokangas R.K., Ristkari T., Plathin M., Huttunen J., Ilonen T., Suomela T., Korkeila J., McGlashan T.H. PROD-screen-a screen for prodromal symptoms of psychosis. Int. J. Methods Psychiatr. Res. 2003, 12(2):92-104.
5. Kelleher I., Harley M., Murtagh A., Cannon M. Are screening instruments valid for psychotic-like experiences? A validation study of screening questions for psychotic-like experiences using in-depth clinical interview. Schizophr. Bull. 2011, 37(2):362-369.
6. Kobayashi H., Nemoto T., Koshikawa H., Osono Y., Yamazawa R., Murakami M., Kashima H., Mizuno M. A self-reported instrument for prodromal symptoms of psychosis: testing the clinical validity of the PRIME Screen-Revised (PS-R) in a Japanese population. Schizophr. Res. 2008, 106(2-3):356-362.
7. Konings M., Bak M., Hanssen M., van Os J., Krabbendam L. Validity and reliability of the CAPE: a self-report instrument for the measurement of psychotic experiences in the general population. Acta Psychiatr. Scand. 2006, 114(1):55-61.
8. Liraud F., Droulout T., Parrot M., Verdoux H. Agreement between self-rated and clinically assessed symptoms in subjects with psychosis. J. Nerv. Ment. Dis. 2004, 192(5):352-356.
9. Loewy R.L., Bearden C.E., Johnson J.K., Raine A., Cannon T.D. The prodromal questionnaire (PQ): preliminary validation of a self-report screening measure for prodromal and psychotic syndromes. Schizophr. Res. 2005, 79(1):117-125.
10. Marshall M., Lewis S., Lockwood A., Drake R., Jones P., Croudace T. Association between duration of untreated psychosis and outcome in cohorts of first-episode patients: a systematic review. Arch. Gen. Psychiatry 2005, 62(9):975-983.
11. McGlashan T.H., Zipursky R.B., Perkins D., Addington J., Miller T., Woods S.W., Hawkins K.A., Hoffman R.E., Preda A., Epstein I., Addington D., Lindborg S., Trzaskoma Q., Tohen M., Breier A. Randomized, double-blind trial of olanzapine versus placebo in patients prodromally symptomatic for psychosis. Am. J. Psychiatry 2006, 163(5):790-799.
12. McGorry P.D., Yung A.R., Phillips L.J., Yuen H.P., Francey S., Cosgrave E.M., Germano D., Bravin J., McDonald T., Blair A., Adlard S., Jackson H. Randomized controlled trial of interventions designed to reduce the risk of progression to first-episode psychosis in a clinical sample with subthreshold symptoms. Arch. Gen. Psychiatry 2002, 59(10):921-928.
13. Morrison A.P., French P., Walford L., Lewis S.W., Kilcommons A., Green J., Parker S., Bentall R.P. Cognitive therapy for the prevention of psychosis in people at ultra-high risk: randomised controlled trial. Br. J. Psychiatry 2004, 185:291-297.
14. Müller M., Vetter S., Buchli-Kammermann J., Stieglitz R.D., Stettbacher A., Riecher-Rössler A. The Self-screen-Prodrome as a short screening tool for pre-psychotic states. Schizophr. Res. Nov. 2010, 123(2-3):217-224.
15. Niv N., Cohen A.N., Mintz J., Ventura J., Young A.S. The validity of using patient self-report to assess psychotic symptoms in schizophrenia. Schizophr. Res. 2007, 90(1-3):245-250.
16. Peters E., Joseph S., Day S., Garety P. Measuring delusional ideation: the 21-item Peters et al. Delusions Inventory (PDI). Schizophr. Bull. 2004, 30(4):1005-1022.
17. Rodgers B., Mann S.A. The reliability and validity of PSE assessments by lay interviewers: a national population survey. Psychol. Med. 1986, 16(3):689-700.
18. Stefanis N.C., Hanssen M., Smirnis N.K., Avramopoulos D.A., Evdokimidis I.K., Stefanis C.N., Verdoux H., Van Os J. Evidence that three dimensions of psychosis have a distribution in the general population. Psychol. Med. 2002, 32(2):347-358.
19. van Os J., Delespaul P. Psychosis research at Maastricht University, The Netherlands. Br. J. Psychiatry 2003, 183:559-560.
20. van Os J., Verdoux H., Hanssen M. CAPE (Community Assessment of Psychic Experiences) 1999, Available from: http://cape42.homestead.com/index.html. last accessed on Jan 12th, 2012.
21. Verdoux H., Sorbara F., Gindre C., Swendsen J.D., van Os J. Cannabis use and dimensions of psychosis in a nonclinical population of female subjects. Schizophr. Res. 2003, 59(1):77-84.
22. Walker E.F., Cornblatt B.A., Addington J., Cadenhead K.S., Cannon T.D., McGlashan T.H., Perkins D.O., Seidman L.J., Tsuang M.T., Woods S.W., Heinssen R. The relation of antipsychotic and antidepressant medication with baseline symptoms and symptom progression: a naturalistic study of the North American Prodrome Longitudinal Sample. Schizophr. Res. 2009, 115(1):50-57.
23. Wood S.J., Pantelis C., Velakoulis D., Yücel M., Fornito A., McGorry P.D. Progressive changes in the development toward schizophrenia: studies in subjects at increased symptomatic risk. Schizophr. Bull. 2008, 34(2):322-329.
24. Yung A.R., Phillips L.J., McGorry P.D., McFarlane C.A., Francey S., Harrigan S., Patton G.C., Jackson H.J. Prediction of psychosis. A step towards indicated prevention of schizophrenia. Br. J. Psychiatry Suppl. 1998, 172(33):14-20.
25. Yung A.R., Phillips L.J., Yuen H.P., Francey S.M., McFarlane C.A., Hallgren M., McGorry P.D. Psychosis prediction: 12-month follow up of a high-risk ("prodromal") group. Schizophr. Res. 2003, 60(1):21-32.
26. Yung A.R., Yuen H.P., McGorry P.D., Phillips L.J., Kelly D., Dell'Olio M., Francey S.M., Cosgrave E.M., Killackey E., Stanford C., Godfrey K., Buckby J. Mapping the onset of psychosis: the Comprehensive Assessment of At-Risk Mental States. Aust. N. Z. J. Psychiatry 2005, 39(11-12):964-971.
27. Yung A.R., Yuen H.P., Berger G., Francey S., Hung T.C., Nelson B., Phillips L., McGorry P. Declining transition rate in ultra high risk (prodromal) services: dilution or reduction of risk?. Schizophr. Bull. 2007, 33(3):673-681.